Daxor unveils next-gen BVA analyzer at HFSA annual meeting

Daxor (DXR) Corporation will exhibit at the Heart Failure Society of America Annual Scientific Meeting in Minneapolis, Minnesota, from September 26-29, 2025. The company will debut its newly FDA-cleared, next-generation blood volume analyzer, signaling a new era of data-driven fluid management for a multi-billion-dollar market. The new analyzer is a significant advancement in the field, designed to unlock widespread adoption of BVA-guided care. The device is three times faster than its predecessor, the BVA-100, requires 50% less blood to be drawn from the patient, and delivers over 95% accuracy from a rapid, lightweight, and battery-operated system.